The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy - Top-Institutions - MDSpire

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

  • By

  • Raffaella Greco

  • Isabel Sánchez-Ortega

  • Antonio M. Risitano

  • Krzysztof Kalwak

  • Annalisa Ruggeri

  • Iliana Kleovoulou

  • Marina Atlija

  • Tobias Alexander

  • Emanuele Angelucci

  • Dina Averbuch

  • Ali Bazarbachi

  • Maria Ester Bernardo

  • Charles Crawley

  • Mette D. Hazenberg

  • Olaf Penack

  • Helen Baldomero

  • Jakob R. Passweg

  • Ibrahim Yakoub-Agha

  • Donal P. McLornan

  • Fabio Ciceri

  • Anna Sureda

  • May 27, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    European Society for Blood and Marrow Transplantation
    European Society for Blood and Marrow Transplantation

    N/A, N/A

    Key Differentiators

    • Hematology

  • #2

    Medical University of Vienna
    Medical University of Vienna

    Vienna, Austria

    Key Differentiators

    • Hematology

  • #3

    University of Genoa
    University of Genoa

    Genoa, Italy

    Key Differentiators

    • Hematology

  • #4

    Karolinska Institute
    Karolinska Institute

    Stockholm, Sweden

    Key Differentiators

    • Hematology

  • #5

    University College London
    University College London

    London, United Kingdom

    Key Differentiators

    • Hematology

Original Source(s)

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

  • by Raffaella Greco, Isabel Sánchez-Ortega, Antonio M. Risitano, Krzysztof Kalwak, Annalisa Ruggeri, Iliana Kleovoulou, Marina Atlija, Tobias Alexander, Emanuele Angelucci, Dina Averbuch, Ali Bazarbachi, Maria Ester Bernardo, Charles Crawley, Mette D. Hazenberg, Olaf Penack, Helen Baldomero, Jakob R. Passweg, Ibrahim Yakoub-Agha, Donal P. McLornan, Fabio Ciceri, Anna Sureda

  • May 27, 2026

Related Content

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report